February 2022 in “Endocrine connections” People with reproductive, thyroid disorders, and type 2 diabetes can experience voice changes, but more research is needed to understand this better.
January 2022 in “Sustainable development goals series” The document concludes that significant investment in agricultural innovation is necessary to achieve global food security and nutrition.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
April 2021 in “Research Square (Research Square)” Achieving 80% or more scalp hair regrowth is considered a successful treatment for significant hair loss.
67 citations,
January 2013 in “Indian Journal of Dermatology, Venereology and Leprology” The document concludes that alopecia areata is an autoimmune disease without a definitive cure, but treatments like corticosteroids are commonly used.
66 citations,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
48 citations,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
43 citations,
November 2009 in “Archives of dermatology” Alefacept does not effectively treat severe alopecia areata.
38 citations,
June 2015 in “PubMed” Calcipotriol cream can effectively and safely treat mild-to-moderate patchy hair loss.
28 citations,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
28 citations,
April 2017 in “Journal of cosmetic dermatology” Low vitamin D can worsen pediatric alopecia areata.
14 citations,
January 2011 in “International Journal of Trichology” Some people with severe, long-lasting baldness responded well to a specific combination treatment.
12 citations,
January 2016 in “Journal of Clinical and Investigative Dermatology” Low vitamin D levels are common in people with Alopecia Areata.
12 citations,
January 2011 in “Photodermatology, photoimmunology & photomedicine” This therapy effectively treats resistant alopecia areata with minimal side effects.
11 citations,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
11 citations,
December 2018 in “Journal of the European Academy of Dermatology and Venereology” Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
10 citations,
September 2014 in “European Journal of Dermatology” A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.
9 citations,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
9 citations,
May 2021 in “International Journal of Dermatology” The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
6 citations,
February 2021 in “Advances in Clinical and Experimental Medicine” Wharton's jelly-derived stem cells were safely used to treat four alopecia patients, resulting in hair regrowth in all of them.
5 citations,
April 2019 in “Journal of Nepal Health Research Council” People with Alopecia areata often have lower vitamin D levels, which may be linked to the severity of their condition.
5 citations,
August 2018 in “PubMed” An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.
4 citations,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
4 citations,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
2 citations,
January 2023 in “Dermatology Practical & Conceptual” AB+ blood group is more common in alopecia areata patients.
2 citations,
September 2022 in “Dermatologic Therapy” Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
2 citations,
May 2022 in “JAAD Case Reports” A woman lost all her hair after mild COVID-19, but it started to regrow after treatment with a specific medication.
2 citations,
December 2018 in “Journal of cosmetic dermatology” Higher CRBP1 levels are linked to more severe alopecia areata.
2 citations,
February 2014 in “Hair therapy & transplantation” Alopecia Areata is an autoimmune condition causing hair loss, influenced by genetics, environment, and possibly improved by anti-MIF therapy, with many patients experiencing regrowth within a year.
1 citations,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.